Clinical trials: CONTROL Condition
Atopic Dermatitis
A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
This double-blind, placebo-controlled study is designed to evaluate the safety and efficacy of ENV-294 in adults with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT07643766
- Testing
- ENV-294
- Where
- 9 sites in United States
- Volunteers
- 200 people
- Sponsor
- Enveda Therapeutics
Type 2 Diabetes
An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets
The purpose of this clinical research study is to learn if initiating treatment with BMS-51248 (Dapagliflozin) in combination with metformin XR can improve diabetes control in patients with Type 2 Diabetes who do not receive any…
- Trial name
- NCT00643851
- Testing
- Dapagliflozin, Metformin XR
- Where
- 99 sites in United States, Mexico and 5 more
- Volunteers
- 994 people
- Sponsor
- AstraZeneca
Covid19
A Phase III Confirmatory Study of K-237
The efficacy and safety of K-237 0.3-0.4 mg/kg orally administered once daily for 3 days will be evaluated in patients with mild COVID-19 using a randomized, double-blind, parallel-group comparative method with placebo as a…
- Trial name
- NCT05056883
- Testing
- K-237 0.3-0.4mg/kg (once daily)
- Where
- 55 sites in Japan, Thailand
- Volunteers
- 1,030 people
- Sponsor
- Kowa Company, Ltd.
Obstructive Sleep Apnea
A Study to Investigate the Effects of ACT-541468 on Nighttime Respiratory Function in Patients With Mild to Moderate Obstructive Sleep Apnea
This study is conducted to investigate the effects of ACT-541468 on nighttime respiratory function in patients with mild to moderate obstructive sleep apnea
- Trial name
- NCT03765294
- Testing
- ACT-541468
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Acute Agitation
Safety and Tolerability of INP105 (Olanzapine by I231 POD® Device) Nasal Spray in Healthy Volunteers - SNAP 101
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of INP105, which is an investigational drug-device combination product comprised of the drug component OLZ administered by a…
- Trial name
- SNAP101 (NCT03624322)
- Testing
- Zyprexa IM, Zydis, INP105
- Where
- Australia
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Impel Pharmaceuticals
Macular Degeneration
Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration
The objective of this study is to evaluate the safety and preliminary efficacy of three doses of Cand5. Cand5, a small interfering RNA molecule that selectively silences the mRNA encoding for VEGF.
- Trial name
- NCT00259753
- Testing
- Bevasiranib
- Where
- 23 sites in United States
- Volunteers
- 120 people
- Sponsor
- OPKO Health, Inc.
Heart Failure, Heart Decompensation
A Phase IIb Study to Investigate the Efficacy and Tolerability of Cinaciguat (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
A placebo controlled, double-blind and randomized study to assess different doses of a new drug (BAY58-2667) given intravenously, to evaluate if it is safe and can help to improve the well-being of patients with acute…
- Trial name
- COMPOSE EARLY (NCT01064037)
- Testing
- Cinaciguat (BAY58-2667)
- Where
- 70 sites in United States, Canada and 14 more
- Volunteers
- 62 people
- Sponsor
- Bayer
Irritable Bowel Syndrome
Effect of BIO-K+ on Symptoms of Irritable Bowel Syndrome
The purpose of this study is to evaluate the safety and effectiveness of Bio-K+ on symptoms of IBS.
- Trial name
- NCT01545037
- Testing
- L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®
- Where
- 3 sites in United States
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Bio-K Plus International Inc.
COVID-19
Study of COVID-19 DNA Vaccine (AG0301-COVID19)
This study will assess the safety and immunogenicity of AG0301-COVID19 in healthy adult volunteers.
- Trial name
- NCT04463472
- Testing
- AG0301-COVID19
- Where
- Japan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AnGes, Inc.
Healthy Volunteers
Study to Investigate the Influence of CKD-519 on 24-h Ambulatory Blood Pressure in Healthy Adult Volunteers
The purpose of this study is to determine influence of CKD-519 on 24-h ambulatory blood pressure after oral administration in healthy adult volunteers.
- Trial name
- NCT02916901
- Testing
- CKD-519 200mg
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Diabetic Neuropathy, Painful; Diabetic Neuropathies
Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability
This is a 2-part study. In Part 1 of the study, subjects will undergo a pain reporting training program in which a painful stimulus will be applied to the subject's hand, and the subjects will be asked to report how painful the…
- Trial name
- NCT01928381
- Testing
- AZD5213 + pregabalin, pregabalin capsules
- Where
- 9 sites in United States
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Infections, Papillomavirus
Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18
Human Papilloma virus (HPV) are viruses that cause a common infection of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can infect the cervix (part of the…
- Trial name
- NCT00122681
- Testing
- Cervarix™, Havrix™-based investigational formulation
- Where
- 138 sites in United States, Australia and 12 more
- Volunteers
- 18,729 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide
PH-797804 is an oral anti-inflammatory drug that may reduce the inflammation that is associated with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT01543919
- Testing
- PH-797804
- Where
- 132 sites in United States, Argentina and 12 more
- Volunteers
- 730 people
- Sponsor
- Pfizer
Rheumatoid Arthritis (RA)
A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)
The purpose of this study is to verify the superiority of ASP015K in combination with MTX or with other disease-modifying antirheumatic drugs (DMARDs) over placebo in terms of efficacy in participants with rheumatoid arthritis…
- Trial name
- NCT03660059
- Testing
- Peficitinib, Plaebo, Disease-modifying antirheumatic drugs (DMARDs)
- Where
- 43 sites in China, South Korea and 1 more
- Volunteers
- 385 people
- Sponsor
- Astellas Pharma China, Inc.
Actinic Keratoses
Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis
Fluorouracil is recommended for the topical treatment of multiple actinic or solar keratoses. In the 5% strength, it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical…
- Trial name
- NCT05078827
- Testing
- Test Product (A): Fluorouracil Cream, 5% topical cream, Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A.
- Where
- 7 sites in United States
- Volunteers
- 458 people
- Sponsor
- Encube Ethicals Pvt. Ltd.
Venous Leg Ulcer, Chronic Wounds
Evaluation of the Efficacy of Hyalomatrix® in the Healing of Chronic Venous Leg Ulcers
This is a randomized controlled trial evaluating the efficacy of HYALOMATRIX in conjunction with standard of care vs. standard of care alone in treating venous leg ulcers.
- Trial name
- NCT07335861
- Testing
- Hyalomatrix, Standard of Care
- Where
- 4 sites in United States
- Volunteers
- 122 people
- Sponsor
- NuScience Medical Biologics, LLC
Alzheimer Disease
Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease
The purpose of the study is to evaluate the safety and tolerability of multiple doses of NPT088 in patients with mild to moderate probable Alzheimer's Disease.
- Trial name
- NCT03008161
- Testing
- NPT088
- Where
- 23 sites in United States
- Volunteers
- 83 people
- Sponsor
- Proclara Biosciences, Inc.
Parkinson Disease, Movement Disorders
Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease
This study evaluates the safety and tolerability of CDNF in patients with Parkinson's disease, when dosed directly into the brain using an implanted investigational drug delivery system (DDS).
- Conditions
- Parkinson Disease, Movement Disorders, Neurodegenerative Diseases, Nervous System Diseases
- Trial name
- NCT03295786
- Testing
- Cerebral Dopamine Neurotrophic Factor, Renishaw Drug Delivery System
- Where
- 3 sites in Finland, Sweden
- Volunteers
- 17 people
- Sponsor
- Herantis Pharma Plc.
Dry Eye Disease
Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye Disease
The goal of this clinical trial is to learn about licaminlimab (OCS-02) in the treatment of dry eye disease. The main question it aims to answer is if licaminlimab ophthalmic solution is more effective than vehicle in treating…
- Trial name
- RELIEF (NCT05896670)
- Testing
- licaminlimab, vehicle of OCS-02, Artificial tears
- Where
- 5 sites in United States
- Volunteers
- 122 people
- Sponsor
- Oculis
Pulmonary Emphysema in Alpha-1 PI Deficiency
Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)
This is a multi-center, randomized, placebo-controlled, double blind clinical study to assess the efficacy and safety of two separate dose regimens of Alpha-1 MP versus placebo for 156 weeks (i.e., 3 years) using computed…
- Trial name
- SPARTA (NCT01983241)
- Testing
- Alpha-1 MP, 0.9% Sodium Chloride for Injection, USP
- Where
- 52 sites in United States, Argentina and 15 more
- Volunteers
- 345 people
- Sponsor
- Grifols Therapeutics LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.